Latest News - Rosacea

Thursday, January 19, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Allergan

FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosacea

The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that eval…

Read the full story

Wednesday, January 18, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com

First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Study

The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin re…

Read the full story

Wednesday, January 04, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Study Examines Diversity in Dermatologic Clinical Trials

Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, es…

Read the full story

Monday, November 28, 2016 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Study: Anxiety Linked to Skin Disease

Anxiety disorders tend to be followed by skin diseases, according to psychologists at the University of Basel in Switzerland and Ruhr University Bochum in Germany. The study, which appears in the j…

Read the full story

Tuesday, September 20, 2016 | PracticalDermatology.com, Research and Publications, National Rosacea Society

National Rosacea Society Awards Three New Grants

The National Rosacea Society (NRS) is funding three new studies in addition to continuing support for two ongoing studies as part of its research grants program. In this round, Luis Garza, MD, an a…

Read the full story

Thursday, September 01, 2016 | Business of Medicine, PracticalDermatology.com, Practice Development, Product Launches and Updates, National Rosacea Society

Vivacare and the National Rosacea Society Collaborate on Patient Education Resource

Vivacare has launched a new Rosacea Education Kit to support dermatologists in the delivery of care to their rosacea patients. The Kit is available at no cost by enrolling online. Upon enrolling, d…

Read the full story

Monday, August 01, 2016 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, La Roche-Posay

Deadline Approaching: Apply for Grant from La Roche-Posay’s "Dermatologist from the Heart" Program

La Roche-Posay plans to continue its "Dermatologist from the Heart" program for the fifth year. As part of the program, La Roche-Posay provides grant money up to $10,000 to fund community…

Read the full story

Thursday, May 26, 2016 | PracticalDermatology.com, Product Launches and Updates, Galderma

Galderma Introduces New Mirvaso Pump Dispenser to Treat Persistent Facial Redness of Rosacea

Galderma Laboratories, L.P. launched  a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33% for the treatment of the persistent facial redness associated with rosacea. The Mirv…

Read the full story

Tuesday, May 24, 2016 | PracticalDermatology.com, Allergan

FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythema

The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial eryt…

Read the full story

Tuesday, May 03, 2016 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Research and Publications, AbbVie, Johnson & Johnson

Global Derm Market Set to Soar Through 2022

The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%, GBI Research reports. This rise will occur despit…

Read the full story

Monday, May 02, 2016 | PracticalDermatology.com, Research and Publications, National Rosacea Society

Study IDs Rosacea-Alzheimers Link

Rosacea may be linked to an increased risk of dementia -- in particular Alzheimer’s disease, new research suggests. This risk was highest in older patients and in patients where rosacea was d…

Read the full story

Friday, April 15, 2016 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, American Academy of Dermatology

Recent AAD Meeting Boasts Record Attendance

More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 ed…

Read the full story

Friday, April 01, 2016 | PracticalDermatology.com, Galderma, National Rosacea Society

Rosacea Awareness Month Highlights Potential Increased Health Risks

New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses.…

Read the full story

Tuesday, February 09, 2016 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com

Hilary Baldwin, MD, Named Medical Director of ATRC

The newly opened Acne Treatment and Research Center (ATRC) in Morristown, NJ, has tapped Hilary Baldwin, MD, to serve as its medical director. Dr. Baldwin received her BA and MA in biology fro…

Read the full story

Tuesday, February 09, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Promius

FDA Awards Tentative Approval for Zenavod to Treat Rosacea

The FDA awarded Dr. Reddy's Laboratories tentative approval for Zenavod™ (doxycycline) Capsules, 40mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory l…

Read the full story
Load More